Eczema Area and Severity Index (EASI)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۶

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۶

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۶

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۶

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

حداقل ۰ — حداکثر ۳

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
easi score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Clear0–0
  • Almost Clear0.1–1
  • Mild1.1–7
  • Moderate7.1–21
Direct Clinical Answer

The Eczema Area and Severity Index (EASI) calculates quantifying total body surface area involvement and staging cutaneous or blistering disease severity. Key inputs include age category. Scores guide calculating resuscitation fluid protocols, administering topical or systemic corticosteroids, and wound care. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Stratifies eczema severity by assessing area involvement and severity signs across four body regions (head/neck, upper extremities, trunk, lower extremities) with validated clinical scoring.

Clinical Indication

The Eczema Area and Severity Index (EASI) is indicated for bedside clinical practice to support Stratifies eczema severity by assessing area involvement and severity signs across four body regions (head/neck, upper extremities, trunk, lower extremities) with validated clinical scoring.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute thermal burns, extensive bullous eruptions, severe psoriasis, or severe cutaneous adverse reactions. Clinical application is indicated across Dermatology clinics, burn centers, and emergency dermatology triage.

Limitations & Contraindications

Rule of Nines overestimates burn surface area in pediatric anatomy; Lund-Browder charts must be utilized.

Clinical Pearls & Action Plan

Full-body cutaneous examination including all mucous membranes and scalp is necessary to detect early epidermal detachment. Guideline pearl: Recommended for clinical trials and research as primary efficacy endpoint..

Formula & Variables:

EASI = 0.1 × (erythema + edema + excoriation + lichenification) × area_score × head_neck_multiplier + 0.2 × (erythema + edema + excoriation + lichenification) × area_score × upper_extremities_multiplier + 0.3 × (erythema + edema + excoriation + lichenification) × area_score × trunk_multiplier + 0.4 × (erythema + edema + excoriation + lichenification) × area_score × lower_extremities_multiplier. Regional multipliers: Head/neck = 0.1 (adults), 0.2 (children 0-7); Upper extremities = 0.2; Trunk = 0.3; Lower extremities = 0.4.

Input Parameters

NameTypeRequiredDescription
age_categorystringYesPatient age category for regional multiplier calculation
head_neck_areaintegerYesHead and neck area involvement score (0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%)
head_neck_erythemaintegerYesHead and neck erythema severity (0=absent, 1=mild, 2=moderate, 3=severe)
head_neck_edemaintegerYesHead and neck edema/papulation severity (0=absent, 1=mild, 2=moderate, 3=severe)
head_neck_excoriationintegerYesHead and neck excoriation severity (0=absent, 1=mild, 2=moderate, 3=severe)
head_neck_lichenificationintegerYesHead and neck lichenification severity (0=absent, 1=mild, 2=moderate, 3=severe)
upper_extremities_areaintegerYesUpper extremities area involvement score (0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%)
upper_extremities_erythemaintegerYesUpper extremities erythema severity (0=absent, 1=mild, 2=moderate, 3=severe)
upper_extremities_edemaintegerYesUpper extremities edema/papulation severity (0=absent, 1=mild, 2=moderate, 3=severe)
upper_extremities_excoriationintegerYesUpper extremities excoriation severity (0=absent, 1=mild, 2=moderate, 3=severe)
upper_extremities_lichenificationintegerYesUpper extremities lichenification severity (0=absent, 1=mild, 2=moderate, 3=severe)
trunk_areaintegerYesTrunk area involvement score (0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%)
trunk_erythemaintegerYesTrunk erythema severity (0=absent, 1=mild, 2=moderate, 3=severe)
trunk_edemaintegerYesTrunk edema/papulation severity (0=absent, 1=mild, 2=moderate, 3=severe)
trunk_excoriationintegerYesTrunk excoriation severity (0=absent, 1=mild, 2=moderate, 3=severe)
trunk_lichenificationintegerYesTrunk lichenification severity (0=absent, 1=mild, 2=moderate, 3=severe)
lower_extremities_areaintegerYesLower extremities area involvement score (0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%)
lower_extremities_erythemaintegerYesLower extremities erythema severity (0=absent, 1=mild, 2=moderate, 3=severe)
lower_extremities_edemaintegerYesLower extremities edema/papulation severity (0=absent, 1=mild, 2=moderate, 3=severe)
lower_extremities_excoriationintegerYesLower extremities excoriation severity (0=absent, 1=mild, 2=moderate, 3=severe)
lower_extremities_lichenificationintegerYesLower extremities lichenification severity (0=absent, 1=mild, 2=moderate, 3=severe)

Score Interpretation & Guidance

RangeStageDescription
0–0ClearNo eczema
0.1–1Almost ClearAlmost clear eczema
1.1–7MildMild eczema
7.1–21ModerateModerate eczema
21.1–50SevereSevere eczema
50.1–72Very SevereVery severe eczema

Evidence-Based References (EBM)

  • Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x.DOI: 10.1034/j.1600-0625.2001.100102.x
  • Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008.DOI: 10.1016/j.jaci.2013.07.008
  • Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401.DOI: 10.1111/all.13401
  • Silverberg JI, Paller AS, Fishbein AB, Kaplan DH, Simpson EL. Eczema prevalence, severity and impact in the United States. Dermatitis. 2019;30(1):66-72. doi: 10.1097/DER.0000000000000408.DOI: 10.1097/DER.0000000000000408

Related calculators